Description

Ziconotide Polyacetate CAS NO 107452-89-1 is a synthetic peptide analog of ω-conotoxin MVIIA, a potent and selective N-type voltage-gated calcium channel blocker. This compound is of paramount importance in advanced pharmaceutical research and development due to its non-opioid mechanism for managing severe chronic pain. It is primarily required by biotechnology firms, pharmaceutical manufacturers, and research institutions focused on developing novel neurotherapeutics and analgesic agents.

Application

• Pharmaceutical Active Ingredient (API): Core component in the formulation of intrathecal analgesics for severe, chronic pain management.
• Neuroscience Research: A critical tool for studying N-type calcium channel function, neuronal signaling, and pain pathways in vitro and in vivo.
• Drug Discovery & Development: Used as a reference standard and lead compound in the development of new non-addictive pain therapies.
• Preclinical Studies: Employed in animal models to investigate efficacy, pharmacokinetics, and safety profiles of calcium channel blockers.
• Analytical Standard: Serves as a high-purity standard for quality control (QC) and analytical method development (e.g., HPLC, MS) in pharmaceutical labs.
• Bioconjugation & Peptide Chemistry: Used as a substrate for developing peptide-drug conjugates or studying structure-activity relationships (SAR).

Basic Information

Product Name	Ziconotide Polyacetate
CAS No.	107452-89-1
Molecular Formula	C₁₀₂H₁₇₂N₃₆O₃₂S₇ • (C₂H₄O₂)ₓ
Molecular Weight	2639.1 g/mol (for peptide base)
Synonyms	Ziconotide Acetate; SNX-111; ω-Conotoxin MVIIA Synthetic Analog; CI-1009; Prialt® (Brand Name); (L-Cysteinyl-L-methionyl-L-α-aspartyl-L-tyrosyl-L-cysteinyl-L-cysteinyl-L-threonylglycyl-L-seryl-L-cysteinyl-L-lysyl-L-asparaginyl-L-phenylalanyl-L-cysteinyl-L-lysyl-L-cysteinyl-L-tyrosyl-L-cysteinyl-L-arginyl-L-leucyl-L-methionyl-L-tyrosyl-L-asparaginyl-L-lysyl-L-cysteinyl-L-cysteinyl-L-arginylglycyl-L-cysteinylglycyl-L-cysteinyl-L-α-glutamyl-L-α-glutamyl-L-α-glutamyl-L-cysteinyl-L-seryl-leucyl)cyclic (3→25),(10→26),(17→36)-tris(disulfide) acetate
EINECS	Contact for details

Quality Control

Our Ziconotide Polyacetate is manufactured under strict quality management systems. Each batch undergoes rigorous analytical testing to ensure identity, purity, and potency, meeting the stringent requirements for pharmaceutical research. Certificates of Analysis (COA) detailing comprehensive specifications, including HPLC purity, peptide content, acetate counterion analysis, and endotoxin levels, are provided with every shipment.

Storage

Preserve in a tightly closed container, protected from light. Store at -20°C or below in a dry environment. The product is hygroscopic (moisture-sensitive). Allow the vial to equilibrate to room temperature in a desiccator before opening to prevent condensation and moisture uptake.

Specification

Item	Specification
Appearance	White to off-white lyophilized powder
Identification (HPLC/MS)	Conforms to reference standard
Purity (HPLC)	≥ 98.0%
Peptide Content	≥ 80.0% (by amino acid analysis)
Acetate Content	5.0% - 12.0%
Water Content (KF)	≤ 5.0%
Single Impurity (HPLC)	≤ 1.0%
Total Impurities (HPLC)	≤ 2.0%
Endotoxins	< 10 EU/mg

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.